These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8979747)

  • 1. Live viral vaccine potency: an index for assessing the cold chain system.
    Adu FD; Adedeji AA; Esan JS; Odusanya OG
    Public Health; 1996 Nov; 110(6):325-30. PubMed ID: 8979747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the cold chain technology in South-East, Nigeria using Immunogenicity study on the measles vaccines.
    Oli AN; Agu RU; Ihekwereme CP; Esimone CO
    Pan Afr Med J; 2017; 27(Suppl 3):28. PubMed ID: 29296163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.
    Fowotade A; Okonko IO; Nwabuisi C; Bakare RA; Fadeyi A; Adu FD
    J Immunoassay Immunochem; 2015; 36(2):195-209. PubMed ID: 24825255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
    Omilabu SA; Oyefolu AO; Ojo OO; Audu RA
    Afr J Med Med Sci; 1999; 28(3-4):209-12. PubMed ID: 11205835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-related issues.
    Rev Infect Dis; 1982; 4(5):972-7. PubMed ID: 7146734
    [No Abstract]   [Full Text] [Related]  

  • 6. Field trial of combined yellow fever and measles vaccines among children in Nigeria.
    Adu FD; Omotade OO; Oyedele OI; Ikusika O; Odemuyiwa SO; Onoja AL
    East Afr Med J; 1996 Sep; 73(9):579-82. PubMed ID: 8991237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of potency testing of poliomyelitis and measles vaccines as an integral part of cold chain surveillance.
    Saraswathy TS; Sinniah M; Lee WS; Lee PC
    Southeast Asian J Trop Med Public Health; 1993 Jun; 24(2):265-8. PubMed ID: 8266228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of yellow fever vaccine.
    Monath TP
    Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the cold chain and follow-up of the potency of the antimeasles vaccine in the field].
    Camacho-Amor ML; Valdespino-Gómez JL; Ayala-González M; Díaz-Ortega JL; González-Velázquez MS; Morales-Romo A; Chávez-San Juan R
    Bol Med Hosp Infant Mex; 1990 Jul; 47(7):506-11. PubMed ID: 2206417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative assessment of cold chain management using the outbreak of circulating vaccine-derived polio virus type 2 as a surrogate marker in Oyo State, Nigeria-2019.
    Babatunde OA; Olatunji MB; Omotajo OR; Ikwunne OI; Hamzat Z; Sola ST
    Pan Afr Med J; 2020; 37():313. PubMed ID: 33654532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children.
    Ruben FL; Smith EA; Foster SO; Casey HL; Pifer JM; Wallace RB; Atta AI; Jones WL; Arnold RB; Teller BE; Shaikh ZQ; Lourie B; Eddins DL; Doko SM; Foege WH
    Bull World Health Organ; 1973; 48(2):175-81. PubMed ID: 4541683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cold chain and the expanded program on immunization in Chile: an evaluation exercise.
    Carrasco R; Dinstrans R; Montaldo I; Medina E; Reyes M; Vergara I; Piwonka A; Thomas ER
    Bull Pan Am Health Organ; 1982; 16(3):261-71. PubMed ID: 7171891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Storage and handling of vaccines by family doctors.
    Finnegan P; Howell F
    Ir Med J; 1996; 89(2):64-6, 68. PubMed ID: 8682634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
    Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
    Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria.
    Monath TP; Nasidi A
    Am J Trop Med Hyg; 1993 Feb; 48(2):274-99. PubMed ID: 8447531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency of oral polio vaccine stored at distribution centers in Madras.
    Deivanayagam N; Vasudevan S; Ashok TP; Ahmed SS
    Indian J Pediatr; 1990; 57(6):757-61. PubMed ID: 2131305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine.
    Stefano I; Sato HK; Pannuti CS; Omoto TM; Mann G; Freire MS; Yamamura AM; Vasconcelos PF; Oselka GW; Weckx LW; Salgado MF; Noale LF; Souza VA
    Vaccine; 1999 Mar; 17(9-10):1042-6. PubMed ID: 10195613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power cuts and EPI vaccine storage.
    Senanayake MP; Perera AS; De Silva TU
    Ceylon Med J; 1997 Jun; 42(2):69-71. PubMed ID: 9257464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The quality standardization of a national vaccine against yellow fever].
    Rasshchepkina MN; Levina VD; Vorob'eva MS; Kozlov VG
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Jul; (7):47-50. PubMed ID: 2251891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The combined measles-yellow fever vaccination in African infants aged 6 to 10 months].
    Mouchon D; Pignon D; Vicens R; Tu-Ha-Thanh ; Tekaia F; Teulières L; Garrigue G
    Bull Soc Pathol Exot; 1990; 83(4):537-51. PubMed ID: 2286007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.